secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2023-05-24T23:59:59+00:00
Accession:  0001104659-23-064177
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Brainstorm Cell Therapeutics COO David Setboun resigns effective May 31, 2023
-----------------------------------------------------------------------------

- David Setboun, PhD, MBA, EVP and COO, notified resignation on May 18, 2023.
- Resignation effective May 31, 2023; he is leaving to pursue another opportunity.
- Dr. Setboun's decision was not due to any disagreement with the company's operations, policies, or practices.
- BCLI has not announced a replacement for the COO role.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923064177/0001104659-23-064177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923064177/tm2316879d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-064177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer